Evidence map›Paper›PMID 33979953›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[Immunotherapy the road of hope for patients with advanced liver cancer in the new era].

H B Ning, K Li, J Shang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. [Multi-omics research contributes to early screening, diagnosis and treatment of liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

H B NingDepartment of Infectious Disease, Henan Provincial People's Hospital, Zhengzhou 450000, China.
K LiDepartment of Infectious Disease, Henan Provincial People's Hospital, Zhengzhou 450000, China.
J ShangDepartment of Infectious Disease, Henan Provincial People's Hospital, Zhengzhou 450000, China.
Henan Provincial People's Hospital · CN

Funding

"Thirteenth Five-Year Plan" National Science and Technology Major Projects 2018ZX10302205-004
6 · The paper itself

Abstract

Liver cancer prevention has always been a key issue in the follow-up diagnosis and treatment of viral hepatitis. Insidious onset, high morbidity, monotherapy, short survival time, and high mortality are the outstanding problems encountered in the diagnosis and treatment of advanced liver cancer. In recent years, with the clinical application of targeted drugs and immune checkpoint inhibitors, phased progress has been made in the diagnosis and treatment of advanced liver cancer, especially the accessibility of drug prices under the new medical insurance has provided more and more patients the opportunity to achieve a longer survival time. In this paper, the hot issues in the diagnosis and treatment of patients with advanced liver cancer in the immunotherapy era are discussed.

Indexed as

Liver NeoplasmsHumansImmunotherapyAdvanced liver cancerImmunotherapyMedical insuranceOverall survival

Identifiers

PMID33979953
PMCPMC12951417
OpenAlexW3163457922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.